This clinical trial investigates the use of metformin in pregnant individuals with preterm preeclampsia. Preeclampsia is a pregnancy complication characterized by high blood pressure and signs of damage to organ systems, particularly the liver and kidneys. When it occurs before 32 weeks of pregnancy, it is called preterm preeclampsia. The study also includes patients with HELLP syndrome, a severe form of preeclampsia that affects the blood and liver, and other hypertensive disorders of pregnancy.
The study aims to determine if metformin can help extend pregnancy duration in individuals with preterm preeclampsia. Participants will receive either metformin tablets or placebo. The medication will be given as film-coated tablets for oral use, with doses up to 3000 mg per day for up to 98 days.
The treatment involves taking the study medication daily until delivery or until it becomes necessary to end the pregnancy for medical reasons. The study will monitor both the mother’s health and the baby’s development throughout the treatment period. The medication will be provided in a modified form (overencapsulated) to ensure that neither the participant nor the healthcare provider knows whether they are receiving metformin or placebo.
The Netherlands 
